Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to NOUS-209 for the prevention of Lynch Syndrome (LS)-associated cancers in LS carriers with genetically confirmed mismatch repair […]
Healthcare Secondaries Manager Revelation Partners Appoints Prashant Gangwal as Partner and CFO
Revelation Partners, the largest secondaries investment manager focused solely on private healthcare, has appointed Prashant Gangwal as partner and chief financial officer. Before joining Revelation Partners, Gangwal was chief financial officer of Altos Ventures, a San Francisco Bay Area-based registered investment advisor that partners with early to growth stage technology companies in consumer and enterprise […]
Medtronic announces intent to acquire SPR Therapeutics, expanding care options for people living with chronic pain
Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the […]
Beyond the Middleman: The PBM Market at an Inflection Point
The Pharmacy Benefit Manager market is undergoing its most significant shift in years. Long-building employer frustration is now converging with rising pharmacy costs, new fiduciary accountability, and landmark regulatory reform — creating real openings for a new generation of platforms. In this white paper, we cover:
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. (“Ajax”), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Lilly to acquire Ajax. Ajax’s lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 […]
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing […]
Revelation Partners Deepens Secondaries Expertise with Appointment of Jonathan Au as Partner and Jordan Bloom as Associate
Revelation Partners, the largest secondaries investment manager focused solely on private healthcare, today announced the appointment of Jonathan Au as partner and Jordan Bloom as associate. These additions further strengthen the firm’s deep expertise in secondary transactions and reinforce its commitment to delivering creative capital solutions to founders, management teams, and other private healthcare stakeholders. Au […]
The Expanding Role of Secondaries — Takeaways from HPE Miami 2026
The Revelation Partners team was back in South Beach, Miami on March 4-5 for this year’s HPE Miami conference, joining a growing group of private equity investors and advisors gathering to discuss the evolving healthcare investment landscape. While we are sure the setting helps, it is great to see how much the conference has expanded over the past […]
RoundTable Healthcare Partners Invests in Colorescience, a Premium Skincare and Sun Protection Brand
RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, today announced a partnership and investment in Colorescience, Inc. (“Colorescience” or the “Company”). Terms of the transaction were not disclosed. Founded on a science-first approach to skincare and sun protection, Colorescience is best known for its mineral-based, clinically validated products […]
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
BASEL, Switzerland – January 16, 2026 – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et al). Publication […]